HALO
NASD Halozyme Therapeutics, Inc.$110.48 ↓ -0.31 (-0.28%) Trading Down from the previous close of $110.79
- YTD change
- +64.16%
- vs 20-day SMA
- +0.09%
- vs 200-day SMA
- +39.86%
Price ranges
Price & Performance
+45.36 (+69.33%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 5.4% away from all-time highs of $116.85
- HALO is up 64% since the beginning of the year
- HALO is up 69% over the past 12 months
- HALO is up 3% over the past 1 month
- 13% of all HALO investors are betting against HALO
HALO reads neutral: price sits above both the 20- and 200-day averages, the 12-month move is +69.9%.
- Previous minute
- -$0.01
- Last hour
- +$0.46
- Last 5 days
- +0.07%
- vs 8-day SMA
- +0.38%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.